SALT
LAKE CITY, Sept. 28, 2023 /PRNewswire/
-- A new national survey from Myriad
Genetics Inc., (NASDAQ:MYGN), a leader in genetic
testing and precision medicine, revealed that breast density and
family health history are two misunderstood breast cancer risk
factors.
Experience the full interactive Multichannel News Release
here:
https://www.multivu.com/players/English/9194951-myriad-genetics-cancer-risk-survey-breast-cancer-screenings/
Of the women surveyed:
- 48% do not know what breast density is and 50% are unsure
if it has anything to do with breast cancer risk
- Few women feel like they have all the medical information
they need from their mother's side (19%) and father's side (15%) to
better understand their breast cancer risk
- Nearly a quarter of women reported they don't talk about
health issues in their families as the primary reason they don't
know anything about their mother's and father's family medical
history
Women with dense breast tissue are up
to four times more likely to develop breast cancer compared to
women without dense breasts.1 Higher-density tissue can
make it more difficult to detect breast masses or cancer during a
screening and may require additional imaging tests. The Federal
Drug Administration recently updated mammography
regulations requiring mammography facilities to notify
patients about the density of their breasts by September 2024.
More information is available
here.
About Myriad Genetics Cancer Risk nationwide
survey
Myriad Genetics Cancer Risk Survey is a
nationwide poll conducted online by ACUPOLL Precision Research,
Inc. from June 20-29, 2023 among a
statistically representative sample (n=1632) of U.S. females age
18+. The margin of error in survey results for the total base
population at a 95% confidence interval is +/- 3%.
About Myriad Genetics
Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
MyRisk is the first
hereditary cancer test to incorporate breast density
using Tyrer-Cuzick version 8 (TCv8) and evaluates 48 genes
associated with hereditary cancer risk to identify genetic changes
associated with an increased cancer risk. For more information,
please visit:
https://myriad.com/hcp-myrisk-hereditary-cancer-test/.
1 McCormack VA, dos Santos Silva I. Breast density and parenchymal
patterns as markers of breast cancer risk: a meta-analysis.
Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.
doi: 10.1158/1055-9965.EPI-06-0034
[PubMed] [Google
Scholar]
View original
content:https://www.prnewswire.com/news-releases/breast-cancer-awareness-month-new-cancer-risk-survey-reveals-risk-factors-are-widely-misunderstood-301942351.html
SOURCE Myriad Genetics, Inc.